Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C, Chronic 1Hepatitis C 1Fibrosis 1Diabetes Mellitus 1Cardiovascular Diseases 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 69atezolizumab 54durvalumab 43lenvatinib 42Nivolumab 38pembrolizumab 35tremelimumab 29Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × sofosbuvir-velpatasvir drug combination × 1 year × Clear all
NCT03520660 2026-06-03

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

National Institutes of Health Clinical Center (CC)

Phase 4 Active not recruiting
121 enrolled
Gastrointestinal

Cardiovascular Diseases, Diabetes Mellitus, Fibrosis, Hepatitis C, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡